» Articles » PMID: 23748096

A Preclinical Evaluation of the Discriminative and Reinforcing Properties of Lisdexamfetamine in Comparison to D-amfetamine, Methylphenidate and Modafinil

Overview
Specialties Neurology
Pharmacology
Date 2013 Jun 11
PMID 23748096
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Lisdexamfetamine dimesylate, which consists of L-lysine covalently bound to D-amfetamine, is the first prodrug for treating ADHD. Its metabolic conversion to yield D-amfetamine by rate-limited, enzymatic hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other stimulants shown to be effective in managing ADHD include D-amfetamine, methylphenidate and modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing effects of these compounds were determined in rats using a 2-choice, D-amfetamine (0.5 mg/kg, i.p.)-cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration. Lisdexamfetamine (0.5-1.5 mg/kg [D-amfetamine base], p.o.) generalised to saline when tested 15 min post-dosing, but dose-dependently generalised to d-amfetamine at 60 min. At 120 min, its D-amfetamine-like effects were substantially diminished. At 15 min, methylphenidate (3.0-10 mg/kg, p.o.) and D-amfetamine (0.1-1.5 mg/kg, p.o.) dose-dependently generalised to the intraperitoneal D-amfetamine cue. Switching to the intraperitoneal route reduced the interval required for lisdexamfetamine to be recognised as D-amfetamine-like, but did not alter its potency. Switching to intraperitoneal injection increased the potency of methylphenidate and D-amfetamine by 3.4× and 2.2×, respectively. Modafinil (50-200 mg/kg, i.p.) generalised partially, but not fully, to d-amfetamine. Methylphenidate (0.1, 0.3, 1.0 mg/kg/injection, i.v.) maintained robust self-administration at the 2 highest doses. Neither lisdexamfetamine (0.05, 0.15 or 0.5 mg/kg/injection [D-amfetamine base], i.v.) nor modafinil (0.166, 0.498 or 1.66 mg/kg/injection, i.v.) served as reinforcers. The results reveal important differences between the profiles of these stimulants. Lisdexamfetamine did not serve as a positive reinforcer in cocaine-trained rats, and although it generalised fully to D-amfetamine, its discriminative effects were markedly influenced by its unusual pharmacokinetics.

Citing Articles

Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials.

Nazarova V, Sokolov A, Chubarev V, Tarasov V, Schioth H Front Pharmacol. 2022; 13:1066988.

PMID: 36467081 PMC: 9713849. DOI: 10.3389/fphar.2022.1066988.


New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development.

Heal D, Gosden J, Smith S Curr Top Behav Neurosci. 2022; 57:79-126.

PMID: 35507283 DOI: 10.1007/7854_2022_332.


Open-label pilot study of lisdexamfetamine for cocaine use disorder.

Mariani J, Choi C, Pavlicova M, Mahony A, Brooks D, Grabowski J Am J Drug Alcohol Abuse. 2021; 47(3):402-409.

PMID: 33797985 PMC: 8266739. DOI: 10.1080/00952990.2021.1885677.


Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder.

Tanda G, Hersey M, Hempel B, Xi Z, Newman A Curr Opin Pharmacol. 2020; 56:13-21.

PMID: 32927246 PMC: 8247144. DOI: 10.1016/j.coph.2020.07.007.


Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder.

Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Fukushi A, Saito K Neuropsychopharmacol Rep. 2019; 40(1):52-62.

PMID: 31814294 PMC: 7292222. DOI: 10.1002/npr2.12091.